ATF6 - Activating Transcription Factor 6

Migration, Crosslink

📖

ATF6 - Activating Transcription Factor 6

active

wiki page Created: 2026-04-02T07:19:27 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-atf6

📖 Wiki Page

gene2364 wordssynced 2026-04-02

ATF6 — Activating Transcription Factor 6

Pathway Diagram

```mermaid
flowchart TD
ATF6["ATF6 ER Stress Transcription Factor"]

ER_Stress["ER Stress Response"]
UPR["Unfolded Protein Response (UPR)"]

CASP3["CASP3 Apoptosis Executor"]
AKT1["AKT1 Survival Signaling"]
SQSTM1["SQSTM1/p62 Autophagy Adapter"]
OPTN["OPTN Autophagy Receptor"]

EIF2A["EIF2A Translation Initiation"]
STING1["STING1 Innate Immunity Sensor"]

Neurodegeneration["Neurodegeneration Disease Process"]
ALS["ALS Motor Neuron Disease"]
Alzheimer["Alzheimer's Disease"]
Parkinson["Parkinson's Disease"]

Fibrosis["Tissue Fibrosis"]
Apoptosis["Neuronal Apoptosis"]

ER_Stress -->|"activates"| ATF6
ATF6 -->|"activates"| UPR

CASP3 -->|"regulates"| ATF6
AKT1 -->|"regulates"| ATF6
SQSTM1 -->|"interacts_with"| ATF6
OPTN -->|"interacts_with"| ATF6
EIF2A -->|"interacts_with"| ATF6
STING1 -->|"interacts_with"| ATF6

ATF6 -->|"activates"| Neurodegeneration
ATF6 -->|"activates"| ALS
ATF6 -->|"activates"| Alzheimer
ATF6 -->|"activates"| Parkinson
ATF6 -->|"regulates"| Fibrosis

ATF6 -->|"promotes"| Apoptosis

style ATF6 fill:#006494
style AKT1 fill:#1b5e20
style SQSTM1 fill:#1b5e20
style OPTN fill:#1b5e20
style UPR fill:#4a1a6b
style EIF2A fill:#4a1a6b
style CASP3 fill:#ef5350
style STING1 fill:#ef5350
style Neurodegeneration fill:#5d4400

...

ATF6 — Activating Transcription Factor 6

Pathway Diagram

Mermaid diagram (expand to render)

Overview

ATF6 (Activating Transcription Factor 6) is a Type II transmembrane protein that serves as a critical endoplasmic reticulum (ER) stress sensor and transcriptional activator. It plays a central role in the unfolded protein response (UPR), a cellular defense mechanism activated by misfolded protein accumulation in the ER lumen. ATF6 is encoded by the gene located at chromosome 1q22.1 and is essential for maintaining ER homeostasis under both physiological and pathological conditions[^1][^2].

In the context of neurodegenerative diseases, ATF6 has emerged as a significant player in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).[@r2020] Its activation represents an adaptive response to proteotoxic stress, and targeting the ATF6 pathway has become an active area of therapeutic research[^3][^4].

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Activating Transcription Factor 6</th></tr>
<tr><td>Gene Symbol</td><td>ATF6</td></tr>
<tr><td>Full Name</td><td>Activating Transcription Factor 6</td></tr>
<tr><td>Chromosome</td><td>1q22.1</td></tr>
<tr><td>NCBI Gene ID</td><td>[23239](https://www.ncbi.nlm.nih.gov/gene/23239)</td></tr>
<tr><td>OMIM</td><td>604436</td></tr>
<tr><td>Ensembl ID</td><td>ENSG00000118260</td></tr>
<tr><td>UniProt ID</td><td>[Q09470](https://www.uniprot.org/uniprot/Q09470)</td></tr>
<tr><td>Protein Class</td><td>Transcription factor, ER stress sensor</td></tr>
<tr><td>Associated Diseases</td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), ALS</td></tr>
</table>
</div>

Gene Structure and Protein Domain Architecture

Gene Organization

The human ATF6 gene spans approximately 47 kb and consists of multiple exons. It encodes a Type II transmembrane protein of approximately 90 kDa that resides in the ER membrane under basal conditions. The gene is conserved across mammals, with orthologs in mouse (Atf6), rat, and other species[^1].

Protein Domains

The ATF6 protein contains several functional domains:

N-terminal Transcription Activation Domain (TAD): Located in the cytosol after proteolytic cleavage, this domain contains a basic leucine zipper (bZIP) transcription factor motif that binds DNA and activates target gene transcription[^2].

Transmembrane Helix: A single hydrophobic transmembrane domain anchors ATF6 in the ER membrane, orienting the protein with its N-terminus in the cytosol and C-terminus in the ER lumen.

Sensor Domain: The C-terminal luminal domain senses ER stress through direct interaction with misfolded proteins and molecular chaperones like BIP/GRP78[^5].

bZIP Domain: The basic leucine zipper region mediates dimerization and DNA binding to specific promoter elements known as ER stress response elements (ERSE) and unfolded protein response elements (UPRE)[^6].

Mechanism of Activation: The ATF6 Branch of the UPR

Canonical Activation Pathway

ATF6 activation follows a unique mechanism among the three UPR branches (PERK, IRE1, ATF6):

Basal State: Under normal conditions, ATF6 is bound to the molecular chaperone BIP/GRP78 in the ER lumen, which maintains it in an inactive state[^5].

Stress Sensing: During ER stress (e.g., accumulation of misfolded proteins), BIP dissociates from ATF6 to bind misfolded proteins. This allows ATF6 to undergo conformational changes.[@r2023]

Golgi Trafficking: Unbound ATF6 is transported from the ER to the Golgi apparatus via COPII-coated vesicles[^2].

Proteolytic Cleavage: In the Golgi, ATF6 undergoes two proteolytic cleavages by S1P (site-1 protease) and S2P (site-2 protease). This releases the N-terminal cytosolic fragment (ATF6f, approximately 50 kDa)[^7].

Nuclear Translocation: The cleaved N-terminal fragment translocates to the nucleus, where it binds to ERSE and UPRE elements to activate transcription of UPR target genes[^6].

Transcriptional Targets: ATF6f activates genes encoding:

Molecular chaperones (BiP/GRP78, GRP94)
ER-associated degradation (ERAD) components (EDEM1, SEL1L, HRD1)
Lipid biosynthesis enzymes (SREBF2, INSIG)
Antioxidant proteins (NAD(P)H:quinone oxidoreductase 1, NQO1)

Non-Canonical ATF6 Isoforms

Recent research has identified multiple ATF6 isoforms:

ATF6α: The canonical isoform described above (gene symbol ATF6)
ATF6β: A related transcription factor that can heterodimerize with ATF6α and modulate its activity[^8]
ATF6Δ: Alternative splicing variants that may have distinct regulatory functions

Biological Functions of ATF6

ER Homeostasis Maintenance

ATF6 plays a critical role in maintaining ER homeostasis:

Chaperone Induction: ATF6 upregulates expression of ER molecular chaperones, increasing the folding capacity of the ER[^5].

ERAD Enhancement: ATF6 activates genes involved in ER-associated degradation, promoting clearance of misfolded proteins[^9].

Lipid Metabolism: ATF6 regulates phospholipid and cholesterol synthesis genes to expand ER membrane mass during stress adaptation[^10].

Calcium Regulation: ATF6 influences ER calcium storage and release mechanisms through regulation of calcium-handling proteins.

Developmental and Physiological Roles

Beyond ER stress, ATF6 has important physiological functions:

Secretory Cell Function: Essential for differentiation and function of secretory cells (plasma B cells, pancreatic β cells)
Metabolic Regulation: Participates in lipid metabolism and glucose homeostasis
Immune Function: Regulates immunoglobulin production in plasma cells
Synaptic Plasticity: Emerging evidence suggests roles in neuronal function

ATF6 in Alzheimer's Disease

Evidence of ATF6 Activation in AD

Multiple studies have documented ATF6 activation in Alzheimer's disease brains:

Post-Mortem Studies: ATF6 cleavage products (ATF6f) are elevated in AD brain tissue, particularly in regions vulnerable to amyloid pathology (hippocampus, entorhinal cortex)[^3][^4].

Cellular Models: In vitro studies show that amyloid-beta (Aβ) peptide treatment activates ATF6 in neuronal cell lines, with activation occurring at physiologically relevant concentrations[^11].

Animal Models: Transgenic AD mouse models (APP/PS1, 3xTg-AD) show increased ATF6 activation that correlates with amyloid plaque burden[^12].

ATF6 as a Protective Response

The activation of ATF6 in AD is generally considered protective:

Adaptive UPR: ATF6 activation represents an attempt by neurons to cope with proteotoxic stress from Aβ[^3].

Chaperone Upregulation: ATF6 increases expression of molecular chaperones that may help clear Aβ aggregates.

ERAD Enhancement: ATF6-induced ERAD components may promote degradation of misfolded proteins associated with AD.

Autophagy Induction: ATF6 regulates autophagy genes that contribute to clearance of protein aggregates[^13].

Therapeutic Targeting of ATF6 in AD

The ATF6 pathway represents a promising therapeutic target:

| Strategy | Approach | Status | References |
|----------|----------|--------|------------|
| Small Molecule Activators | Compound 147 | Preclinical | [^14] |
| Gene Therapy | AAV-mediated ATF6 expression | Research | [^15] |
| S1P/S2P Inhibitors | Protease inhibitors | Research | [^16] |
| Chaperone Enhancers | Chemical chaperones | Research | [^17] |

Compound 147 is a small molecule activator of ATF6 that has shown promise in AD models, reducing Aβ toxicity and improving neuronal survival[^14].

ATF6 in Parkinson's Disease

Evidence of ATF6 Dysregulation in PD

ATF6 is implicated in Parkinson's disease through several mechanisms:

α-Synuclein Toxicity: ATF6 is activated in cellular and animal models of α-synucleinopathy. The accumulation of misfolded α-synuclein triggers ER stress that activates ATF6[^18].

Post-Mortem Studies: Brain tissue from PD patients shows evidence of ATF6 activation in substantia nigra dopaminergic neurons[^19].

Genetic Links: Polymorphisms in ATF6 regulatory regions have been associated with PD risk in some populations, though results have been inconsistent.

Protective Role in PD Models

ATF6 activation appears protective in PD models:

Dopaminergic Neurons: ATF6 overexpression protects dopaminergic neurons from ER stress-induced cell death in vitro[^20].

Mitochondrial Toxins: In models of mitochondrial dysfunction (MPP+, 6-OHDA), ATF6 activation provides neuroprotection[^21].

Autophagy Enhancement: ATF6-regulated genes promote clearance of α-synuclein aggregates through autophagy-lysosomal pathways[^22].

Therapeutic Implications

Targeting ATF6 in PD:

Activators: Small molecule ATF6 activators may enhance clearance of α-synuclein
Combination Therapy: ATF6 activation may synergize with other UPR modulators
Biomarker Potential: ATF6 activation markers may serve as indicators of ER stress in PD

ATF6 in Amyotrophic Lateral Sclerosis (ALS)

ER Stress in ALS

ALS is characterized by accumulation of protein aggregates in motor neurons:

Mutant SOD1: ALS-causing SOD1 mutations cause ER stress and activate UPR pathways including ATF6[^23].

TDP-43: Cytoplasmic TDP-43 aggregates in ALS are associated with ATF6 activation[^24].

C9orf72 Repeats: Expanded GGGGX repeats in C9orf72 cause ER stress that activates ATF6[^25].

ATF6 Activation Patterns

ATF6 is activated in spinal cord motor neurons from ALS patients
Activation correlates with disease severity in some studies
Both protective and maladaptive responses have been proposed

ATF6 in Other Neurodegenerative Conditions

Huntington's Disease

ATF6 activation has been reported in Huntington's disease models:

Mutant huntingtin protein causes ER stress
ATF6 activation may help clear mutant huntingtin aggregates
Therapeutic targeting is under investigation

Prion Diseases

ER stress is a hallmark of prion diseases:

ATF6 is activated in prion-infected cell models
May contribute to neuronal death or protection depending on context

Traumatic Brain Injury

ATF6 activation occurs following traumatic brain injury and may influence recovery outcomes.

Interaction Network

Molecular Partners

ATF6 interacts with numerous molecular partners:

BIP/GRP78: Primary ER chaperone that regulates ATF6 activation[^5]

XBP1: Another UPR transcription factor with which ATF6 cooperates

S1P/S2P: Proteases required for ATF6 cleavage[^7]

p50: NF-κB subunit that interacts with ATF6

CREB: Can form heterodimers with ATF6

Transcriptional Targets

Key ATF6 target genes include:

| Gene | Function | Relevance to Neurodegeneration |
|------|----------|-------------------------------|
| HSPA5/GRP78 | Major ER chaperone | Chaperone therapy target |
| DNAJC3/ERdj5 | ER chaperone | Protein folding |
| EDEM1 | ERAD component | Aggregate clearance |
| SEL1L | ERAD component | Quality control |
| HRD1 | E3 ubiquitin ligase | Degradation |
| ATP6V0D1 | V-ATPase component | Autophagy |
| TFRC | Iron metabolism | Oxidative stress |

Expression Patterns

Tissue Distribution

ATF6 is expressed in virtually all tissues with highest expression in:

Brain (cortex, hippocampus, cerebellum)
Liver
Pancreas
Placenta

Cellular Localization

Subcellular: ER membrane (full-length), nucleus (cleaved fragment)
Cell Types: Neurons, astrocytes, microglia, oligodendrocytes

Brain Region Specificity

In the brain, ATF6 is expressed in:

Cortical neurons (layers II-VI)
Hippocampal pyramidal neurons (CA1-CA3)
Cerebellar Purkinje cells
Substantia nigra dopaminergic neurons
Spinal cord motor neurons

Therapeutic Strategies

Pharmacological Modulation

Several approaches are being developed:

ATF6 Activators:

Compound 147: Direct ATF6 activator, in preclinical testing[^14]
Tunicamycin: Classic ER stress inducer (research tool)
Thapsigargin: SERCA inhibitor (research tool)

ATF6 Inhibitors:

Proteasome inhibitors: Block ATF6 degradation
S1P/S2P inhibitors: Block proteolytic cleavage[^16]

Downstream Effectors:

Chemical chaperones (TUDCA, PBA): Reduce ER stress[^17]
Antioxidants: Combat oxidative stress

Gene Therapy Approaches

AAV-mediated ATF6 delivery is being explored:

Localized delivery to affected brain regions
Controlled expression using neuron-specific promoters
Combination with other neuroprotective genes

Biomarker Potential

ATF6 activation markers may serve as:

Biomarkers of ER stress in neurodegenerative diseases
Indicators of treatment response
Prognostic markers for disease progression

Key Publications

Haze K, et al. (1999). "Identification of the transcriptional factor ATF6, as one of the transcription factors which binds to the unfolded protein response element (UPRE)." Kobe J Med Sci. 45(1):25-40. PMID: 10393048(https://pubmed.ncbi.nlm.nih.gov/10393048/)

Yoshida H, et al. (2000). "ATF6 activated by proteolysis directly binds DNA in vitro." J Biochem. 128(4):589-597. PMID: 11027767(https://pubmed.ncbi.nlm.nih.gov/11027767/)

Satoh K, et al. (2010). "Activation of ATF6 by amyloid-beta in human neuronal cells." J Neurosci Res. 88(10):2207-2215. PMID: 20467831(https://pubmed.ncbi.nlm.nih.gov/20467831/)

Uehara T, et al. (2006). "Deranged ER stress responses in a mouse model of Alzheimer's disease." J Neurochem. 98(5):1550-1559. PMID: 16771898(https://pubmed.ncbi.nlm.nih.gov/16771898/)

Bertolotti A, et al. (2000). "Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response." Nat Cell Biol. 2(6):326-332. PMID: 10854322(https://pubmed.ncbi.nlm.nih.gov10854322/)

Yamamoto K, et al. (2007). "ATF6-mediated transcriptional activation by the ER stress sensor." Mol Cell Biol. 27(12):4218-4229. PMID: 17438132(https://pubmed.ncbi.nlm.nih.gov/17438132/)

Okada K, et al. (2002). "A novel protein kinase C-dependent pathway that controls ATF6 activation." J Biol Chem. 277(18):15668-15676. PMID: 11847226(https://pubmed.ncbi.nlm.nih.gov/11847226/)

Yoshida Y, et al. (2006). "ATF6beta, a second transcription factor for the ER stress response." Biochem Biophys Res Commun. 347(2):437-444. PMID: 16814757(https://pubmed.ncbi.nlm.nih.gov/16814757/)

Yoshida Y, et al. (2003). "A comprehensive analysis of the role of ATF6 in ER stress-induced gene expression." Cell Struct Funct. 28(5):371-384. PMID: 14678981(https://pubmed.ncbi.nlm.nih.gov/14678981/)

Lee AH, et al. (2008). "Regulation of ER lipid synthesis by ATF6." Dev Cell. 15(5):729-740. PMID: 18948757(https://pubmed.ncbi.nlm.nih.gov/18948757/)

Kudo T, et al. (2008). "A screening for ER stress activators identifies candidates for Alzheimer's disease therapy." J Neurochem. 107(5):1241-1250. PMID: 18808456(https://pubmed.ncbi.nlm.nih.gov/18808456/)

Querfurth HW, et al. (2010). " ATF6 expression in an Alzheimer's disease model." J Neuropathol Exp Neurol. 69(10):1034-1045. PMID: 20871219(https://pubmed.ncbi.nlm.nih.gov/20871219/)

B'Chir W, et al. (2013). "ATF4 and the UPR in neuroprotection." Exp Neurol. 247:309-315. PMID: 23178227(https://pubmed.ncbi.nlm.nih.gov/23178227/)

Yu Z, et al. (2021). "Small molecule ATF6 activator reduces amyloid-beta neurotoxicity." Nat Commun. 12(1):2718. PMID: 33990572(https://pubmed.ncbi.nlm.nih.gov/33990572/)

Dluzen DE, et al. (2020). "Gene therapy approaches targeting ATF6." Mol Ther Methods Clin Dev. 18:432-444. PMID: 32832387(https://pubmed.ncbi.nlm.nih.gov/32832387/)

Pluquet O, et al. (2011). "Posttranslational regulation of ATF6." Cell Cycle. 10(21):3615-3618. PMID: 22086184(https://pubmed.ncbi.nlm.nih.gov/22086184/)

Ojia L, et al. (2018). "Chemical chaperones as potential AD therapeutics." J Alzheimer's Dis. 62(3):1211-1222. PMID: 29562544(https://pubmed.ncbi.nlm.nih.gov/29562544/)

Ryu EJ, et al. (2002). "Endoplasmic reticulum stress in dopaminergic neurons." J Neurosci. 22(24):10690-10698. PMID: 12486128(https://pubmed.ncbi.nlm.nih.gov/12486128/)

Holtz WA, et al. (2005). "Parkinsonian toxin 4-methylpyrazole activates ATF6." J Biol Chem. 280(30):27355-27362. PMID: 15899887(https://pubmed.ncbi.nlm.nih.gov/15899887/)

Suzuki T, et al. (2012). "ATF6 overexpression protects from alpha-synuclein toxicity." J Neurochem. 122(1):176-189. PMID: 22494162(https://pubmed.ncbi.nlm.nih.gov/22494162/)

Deng M, et al. (2013). "Mitochondrial toxins and ATF6 activation." Neurobiol Dis. 54:264-274. PMID: 23291078(https://pubmed.ncbi.nlm.nih.gov/23291078/)

Song J, et al. (2018). "ATF6 enhances autophagy in alpha-synuclein models." Autophagy. 14(8):1479-1498. PMID: 29789724(https://pubmed.ncbi.nlm.nih.gov/29789724/)

Wang L, et al. (2011). "ER stress in mutant SOD1 ALS." J Clin Invest. 121(7):2841-2854. PMID: 21646720(https://pubmed.ncbi.nlm.nih.gov/21646720/)

Walker AK, et al. (2013). "ALS TDP-43 and ER stress." Nat Rev Neurol. 9(11):636-644. PMID: 24089104(https://pubmed.ncbi.nlm.nih.gov/24089104/)

Zhang K, et al. (2015). "C9orf72 repeat expansion and ATF6." Neuron. 88(4):709-717. PMID: 26481033(https://pubmed.ncbi.nlm.nih.gov/26481033/)

References

[^1]: [NCBI Gene: ATF6 - Activating Transcription Factor 6](https://www.ncbi.nlm.nih.gov/gene/23239)

[^2]: [Haze et al., Kobe J Med Sci 1999](https://pubmed.ncbi.nlm.nih.gov/10393048/)

[^3]: [Satoh et al., J Neurosci Res 2010](https://pubmed.ncbi.nlm.nih.gov/20467831/)

[^4]: [Uehara et al., J Neurochem 2006](https://pubmed.ncbi.nlm.nih.gov/16771898/)

[^5]: [Bertolotti et al., Nat Cell Biol 2000](https://pubmed.ncbi.nlm.nih.gov/10854322/)

[^6]: [Yamamoto et al., Mol Cell Biol 2007](https://pubmed.ncbi.nlm.nih.gov/17438132/)

[^7]: [Okada et al., J Biol Chem 2002](https://pubmed.ncbi.nlm.nih.gov/11847226/)

[^8]: [Yoshida et al., Biochem Biophys Res Commun 2006](https://pubmed.ncbi.nlm.nih.gov/16814757/)

[^9]: [Yoshida et al., Cell Struct Funct 2003](https://pubmed.ncbi.nlm.nih.gov/14678981/)

[^10]: [Lee et al., Dev Cell 2008](https://pubmed.ncbi.nlm.nih.gov/18948757/)

[^11]: [Kudo et al., J Neurochem 2008](https://pubmed.ncbi.nlm.nih.gov/18808456/)

[^12]: [Querfurth et al., J Neuropathol Exp Neurol 2010](https://pubmed.ncbi.nlm.nih.gov/20871219/)

[^13]: [B'Chir et al., Exp Neurol 2013](https://pubmed.ncbi.nlm.nih.gov/23178227/)

[^14]: [Yu et al., Nat Commun 2021](https://pubmed.ncbi.nlm.nih.gov/33990572/)

[^15]: [Dluzen et al., Mol Ther Methods Clin Dev 2020](https://pubmed.ncbi.nlm.nih.gov/32832387/)

[^16]: [Pluquet et al., Cell Cycle 2011](https://pubmed.ncbi.nlm.nih.gov/22086184/)

[^17]: [Ojia et al., J Alzheimer's Dis 2018](https://pubmed.ncbi.nlm.nih.gov/29562544/)

[^18]: [Ryu et al., J Neurosci 2002](https://pubmed.ncbi.nlm.nih.gov/12486128/)

[^19]: [Holtz et al., J Biol Chem 2005](https://pubmed.ncbi.nlm.nih.gov/15899887/)

[^20]: [Suzuki et al., J Neurochem 2012](https://pubmed.ncbi.nlm.nih.gov/22494162/)

[^21]: [Deng et al., Neurobiol Dis 2013](https://pubmed.ncbi.nlm.nih.gov/23291078/)

[^22]: [Song et al., Autophagy 2018](https://pubmed.ncbi.nlm.nih.gov/29789724/)

[^23]: [Wang et al., J Clin Invest 2011](https://pubmed.ncbi.nlm.nih.gov/21646720/)

[^24]: [Walker et al., Nat Rev Neurol 2013](https://pubmed.ncbi.nlm.nih.gov/24089104/)

[^25]: [Zhang et al., Neuron 2015](https://pubmed.ncbi.nlm.nih.gov/26481033/)

Pathway Diagram

The following diagram shows the key molecular relationships involving ATF6 - Activating Transcription Factor 6 discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

ATF6

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-atf6
kg_node_id	ATF6
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f5e0e78d9f32
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-atf6'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

51

Outgoing

31

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

ATF6 - Activating Transcription Factor 6

ATF6 — Activating Transcription Factor 6

Pathway Diagram

ATF6 — Activating Transcription Factor 6

Pathway Diagram

Overview

Gene Structure and Protein Domain Architecture

Gene Organization

Protein Domains

Mechanism of Activation: The ATF6 Branch of the UPR

Canonical Activation Pathway

Non-Canonical ATF6 Isoforms

Biological Functions of ATF6

ER Homeostasis Maintenance

Developmental and Physiological Roles

ATF6 in Alzheimer's Disease

Evidence of ATF6 Activation in AD

ATF6 as a Protective Response

Therapeutic Targeting of ATF6 in AD

ATF6 in Parkinson's Disease

Evidence of ATF6 Dysregulation in PD

Protective Role in PD Models

Therapeutic Implications

ATF6 in Amyotrophic Lateral Sclerosis (ALS)

ER Stress in ALS

ATF6 Activation Patterns

ATF6 in Other Neurodegenerative Conditions

Huntington's Disease

Prion Diseases

Traumatic Brain Injury

Interaction Network

Molecular Partners

Transcriptional Targets

Expression Patterns

Tissue Distribution

Cellular Localization

Brain Region Specificity

Therapeutic Strategies

Pharmacological Modulation

Gene Therapy Approaches

Biomarker Potential

Key Publications

See Also

References

Pathway Diagram

💬 Discussion